1st Biosimilars Act Ruling May Limit Patent Challenges
The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s...To view the full article, register now.
Already a subscriber? Click here to view full article